r-associated antigens, detects up to 40% of lung cancers, including early stage disease (Stages 1 and 2) with a specificity of 90% and an overall accuracy of 88%. The performance of
EarlyCDT-Lung is comparable to mammography in young women at high risk of breast cancer and also colonoscopy in individuals at high risk of colon cancer. Both small cell lung cancer (SCLC) and non-small cell lung cancer (NSCLC) were detected by
EarlyCDT-Lung. The presence of benign lung disease did not impact the high specificity of the test.
Timothy C. Kennedy, M.D., Clinical Professor, University of Colorado School of Medicine, commented about EarlyCDT-Lung and this new data, "It is intriguing to consider the possible impact these test characteristics may have on the management of patients at high risk for lung cancer with suspicious CT imaging results. The positive predictive value is very good and should aid further risk stratification when considering any ongoing monitoring options. The sensitivity is pretty good. Much work needs to be done before the test's impact on lung cancer specific mortality can be determined, especially in the area of early detection."
Previous published studies had focused on the technical performance of the test reporting that EarlyCDT-Lung is a reproducible autoantibody (immuno-biomarker) laboratory test, which gave similar results in training and validation datasets. The present publication extends these findings and in particular highlights that EarlyCDT-Lung detects early stage lung cancer that may significantly improve the prognosis for lung cancer patients.
Currently in the United States, lung cancer is responsible for more deaths than breast, prostate, colon, liver, kidney and melanoma cancers
'/>"/>
SOURCE Oncimmune (USA) LLC Copyright©2010 PR Newswire. All rights reserved | |
Page: 1 2 3 4 5 6 Related biology technology :1.
YM BioSciences announces conclusion of Phase I dose-escalation and expansion of ongoing CYT387 Phase I/II clinical study2.
Aeterna Zentaris Announces NIH Grant for a Phase 1/2 Study in Advanced Prostate Cancer with AEZS-1083.
DAIICHI SANKYO EUROPE GmbH Selects DATATRAK eClinical™ for Pan-European Systolic Hypertension Study4.
New England Journal of Medicine Publishes Data from Pivotal Phase 3 PROVENGE IMPACT Study5.
Angiotech Pharmaceuticals and partner Athersys announce positive results from phase I study of MultiStem(R) in heart attack patients6.
Aegera Therapeutics Reports Survival Data from the Phase 1 Portion of its Phase 1-2 Study of AEG35156 in Combination with Sorafenib in Patients with Advanced Hepatocellular Carcinoma7.
Study measures single-molecule machines in action8.
Recent Study Reports Reveals that HGH May Aid Performance 9.
Study Finds BYETTA(R) Use Was Not Associated With Increased Rate of Acute Pancreatitis Compared to Other Antidiabetic Drugs: Final Results Presented at ADA 201010.
Depth charge: Using atomic force microscopy to study subsurface structures11.
Effective Odor and Pathogen Control in Livestock Operations Revealed in New Case Study